GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 636 participants.

Also called NCT03821129

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 636 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03821129
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03821129. Allocation not applicable; no masking; primary purpose prevention. Start 2019-07-25 (actual); primary completion 2028-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Acronym
REDUCE PAS
Condition
Stroke
Condition
PFO - Patent Foramen Ovale
Intervention (Device)
PFO closure with GORE® CARDIOFORM Septal Occluder
Lead sponsor
W.L.Gore & Associates (class: industry)

Record details

Record id
cardio:ct-nct03821129
Content hash
4a00beb190375def5eeec9d8b41c60d46ebd8644cc197962574d7c8a93dd9851